Skip to main content

Outcomes Summary -- Regulatory Roundtable for Cognitive Impairment in Parkinson's Disease

Alzheimer's Research Forum

This paper outlines the key takeaways and next steps from a discussion MJFF held with 24 key opinion leaders and 16 members of the FDA on mild cognitive impairment in PD (PD-MCI). The topics of the meeting included a review of the PD-MCI diagnostic criteria and plans for validation, existing outcome measures and unmet needs in the field, and the study design for future cognitive impairment trials. This outcomes report represents MJFF's vested interest in filling in some of the research gaps in order to encourage therapeutic development for PD-MCI.


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.